OL-001
Tumor-Anchored Interleukin-12 (IL-12) Immunotherapy for Ovarian Cancer
Technology Overview: Targeting peritoneal metastasis with IL-12-functionalized Layer-by-Layer (LbL) nanoparticles (NPs) is a promising immunotherapeutic approach for late-stage ovarian cancer (OC). The lead candidate, OL-001, consists of a liposomal NP coated with LbL surface films and surface-bound IL-12 designed to selectively anchor onto OC cells within the peritoneal cavity. Importantly, IL-12 is chemically conjugated to the surface of the liposomal construct, enabling prolonged retention of the cytokine directly at the tumor site. Unlike conventional NPs that rely on intracellular uptake, OL-001 is engineered to bind and remain on the surface of tumor cells, creating a localized cytokine depot that sustains immune activation while minimizing systemic exposure and toxicity. Beyond OC, this platform may be applicable to other peritoneal malignancies, including colon, gastric, and pancreatic cancers, and may enable the development of additional tumor-targeted immunotherapies and drug delivery systems.
Technology Highlights: Backed by over a decade of work and dozens of peer-reviewed publications in prestigious journals, the LbL platform is an approach to modify the surface chemistry of NPs, enabling tumor targeting, enhanced pharmacokinetics, and control over cellular uptake.
LbL NP-coated with poly-L-arginine (PLR) and poly-L-glutamate (PLE) selectively localize to metastatic OC lesions within the peritoneal cavity and anchor onto tumor cell surfaces, enabling prolonged therapeutic retention at disease sites.
OL-001 chemically conjugates IL-12 to the surface of the NP rather than encapsulating it internally, creating a tumor-anchored cytokine depot that sustains localized immune activation while minimizing systemic toxicity.
By concentrating and prolonging IL-12 activity directly within metastatic lesions, OL-001 is designed to synergize with CPIs while potentially avoiding the toxicity associated with conventional cytokine or chemotherapy-based immunotherapy combinations.
In metastatic OC models, OL-001 significantly extended survival and sensitized tumors to checkpoint blockade. When combined with CPIs, OL-001 achieved complete tumor eradication and durable immune memory in 100% of treated mice, whereas CPIs alone had minimal activity and free IL-12 combinations cured fewer than 20% of animals.
